Kelaprofen

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kelaprofen

Property Description
Active Ingredient Ketoprofen
Form Oral (tablets, capsules), Topical (gel, patch), Parenteral (injection)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic compound (Propionic acid derivative)

What Type of Medicine is Kelaprofen?

Kelaprofen is the trade designation for the active ingredient Ketoprofen, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This compound is a synthetic pharmaceutical drug belonging to the propionic acid derivative class, distinguishing it chemically from other anti-inflammatory groups. Its high-level pharmacological classification is established within the Anatomical Therapeutic Chemical (ATC) Classification System. This classification identifies the substance as an antirheumatic and anti-inflammatory agent. Unlike some combination products, Kelaprofen is manufactured as a single-component product, focusing entirely on the anti-inflammatory efficacy of Ketoprofen.


Composition and Available Forms of Kelaprofen

The core composition of Kelaprofen features the sole active substance, Ketoprofen, combined with excipients suitable for its finished form. The active ingredient itself is defined chemically as 2-(3-benzoylphenyl)propanoic acid. This describes the precise chemical structure of the active compound. The drug is produced in diverse dosage forms to accommodate various needs, including oral tablets, capsules, and extended-release formulations for systemic absorption, as well as topical gels, transdermal patches, and solutions intended for injection. This broad availability allows for administration tailored to acute or localized discomfort via multiple routes of administration, such as oral, topical, parenteral, and rectal.


What is the General Purpose of Taking Kelaprofen?

The general purpose of Kelaprofen is to provide symptomatic relief by simultaneously exerting analgesic (pain-relieving), anti-inflammatory (swelling-reducing), and antipyretic (fever-reducing) effects. As an NSAID, it assists in managing acute musculoskeletal pain by reducing the signals that drive inflammation. This triple action establishes it as a non-narcotic option for alleviating general symptoms related to inflammatory processes.

Regulatory References

  1. Ketoprofen - LiverTox - NIH

What side effects are possible with Kelaprofen?

Possible Side Effects and Safety Information: Kelaprofen

Kelaprofen, a nonsteroidal anti-inflammatory drug (NSAID), is generally well-tolerated when used as directed, but like all medications, it can cause side effects. Understanding these potential effects is crucial for patient safety.


Common Side Effects

These effects are typically mild and may resolve as your body adjusts to the medication. If they persist or worsen, consult your healthcare provider.

System Side Effect
Gastrointestinal Nausea, indigestion (dyspepsia), stomach pain, diarrhea, constipation.
Central Nervous System Headache, dizziness, drowsiness.

Serious Side Effects and Warnings

Immediate medical attention is required if you experience any signs of a serious reaction.

  • Cardiovascular Risk: Kelaprofen, like other NSAIDs, may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke. This risk may increase with the duration of use and in patients with pre-existing heart disease or risk factors.
  • Gastrointestinal Risk: Serious gastrointestinal bleeding, ulceration, and perforation of the stomach or intestines can occur without warning symptoms. Older patients and those with a history of GI disease are at greater risk.
  • Renal Effects: NSAIDs can cause new-onset or worsening of kidney failure (renal insufficiency).
  • Allergic Reactions: Signs of a severe allergic reaction (anaphylaxis) include swelling of the face, throat, or tongue, difficulty breathing, and rash.

General Safety Information

  • Contraindications: Kelaprofen is typically contraindicated in patients with a known hypersensitivity to the drug or other NSAIDs, in the setting of coronary artery bypass graft (CABG) surgery, and in late pregnancy.
  • Drug Interactions: Inform your doctor of all other medications you are taking, especially blood thinners, corticosteroids, diuretics, and certain blood pressure medications, as interactions may increase the risk of adverse effects.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Kelaprofen (Ketoprofen) documents specific clinical manifestations and severe systemic complications associated with the ingestion of an excessive amount. This information dictates the required emergency response.

Documented Overdose Presentations

Symptoms commonly reported in overdose include nausea, vomiting (potentially with blood or coffee-ground material), abdominal pain, diarrhea, headache, drowsiness, and confusion. Additional effects may include tinnitus (ringing in the ears) or blurred vision. Severe outcomes involve the Gastrointestinal system (serious bleeding, ulceration, and perforation), the Renal system (acute renal failure), and the Central Nervous System (seizures and coma). These manifestations are classified as severe in regulatory documentation.

Emergency Actions and Management

Immediate medical attention must be sought upon suspicion of an overdose. Urgent medical help is required when severe or life-threatening manifestations are observed.

Management is symptomatic and supportive, as regulatory documents state that no specific antidote is known for Ketoprofen overdose. Procedures described in official documents may include gastric decontamination (such as activated charcoal or gastric lavage) and close hospital monitoring, often involving ECG and specific laboratory testing. Official labeling also notes that elderly patients are at a greater risk for serious gastrointestinal events following exposure to an excess dose.

Therapeutic Uses of Kelaprofen

Quick Facts

  • Relief from discomfort: Supports the reduction of pain associated with musculoskeletal issues in horses.
  • Visceral pain management: Used for the temporary management of visceral discomfort related to colic in horses.
  • Supportive care for cattle: Assists in the supportive management of parturient paresis, a condition associated with calving.
  • Fever and distress reduction: Aids in mitigating elevated body temperature (pyrexia) and signs of distress connected to certain bacterial or viral respiratory conditions in cattle and pigs, when used with appropriate concomitant therapy.
  • Recovery support: Indicated as part of a therapeutic regimen to support recovery in cases of acute clinical mastitis in cattle, including cases of acute endotoxin mastitis.

Kelaprofen is indicated for use in specific animal species, including horses, cattle, and pigs, to provide relief from certain clinical signs associated with various health conditions. Its primary role involves supporting the management of pain and inflammation.

In horses, the medication is administered to manage inflammation and discomfort arising from musculoskeletal disorders. It is also used for the symptomatic relief of visceral pain that presents with colic. In cattle, Kelaprofen serves as a supportive measure for the clinical signs associated with calving-related conditions, such as parturient paresis, and assists in the reduction of udder edema.

The medication also has an important role in adjunctive therapy. For both cattle and pigs, it is used to help reduce fever and general distress connected with bacterial or viral respiratory disease. Furthermore, Kelaprofen is employed as part of the overall care plan to support the recovery of cattle with acute clinical mastitis and sows affected by Mastitis Metritis Agalactia Syndrome (MMA).

Eligibility and Restrictions for Use

Kelaprofen (Ketoprofen) is restricted to use in approved species: horses, cattle, and pigs. The drug is contraindicated (must not be used) in animals with specific pre-existing health issues. This includes animals suffering from impaired hepatic, renal, or cardiac function, and those with gastrointestinal lesions, ulceration, or the potential for bleeding. Use is also prohibited in animals with a haemorrhagic diathesis or known hypersensitivity to Ketoprofen or other NSAIDs. The medicine must not be administered concurrently with other NSAIDs or glucocorticoids.

Strict eligibility rules govern age and reproductive status. Kelaprofen is contraindicated in pregnant mares (horses). Its safety has not been established in pregnant sows (pigs), where use requires a careful benefit-risk assessment. Lactating cows and sows are permitted to receive the medicine. Regarding age, the drug is not recommended for foals under 15 days of age, and its use in animals less than 6 weeks of age or in aged animals involves additional risk. Special caution is also required for animals that are severely dehydrated, hypovolemic, or hypotensive.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Kelaprofen (Ketoprofen) mandates restrictions concerning co-administration with several medicinal products and substances. This information strictly details documented interaction patterns, classification, and resulting restrictions.

Contraindicated Combinations

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 inhibitors, and high-dose Acetylsalicylic Acid (Aspirin) is formally contraindicated due to the established risk of severe gastrointestinal bleeding and ulceration. Furthermore, use is prohibited for the management of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Clinically Significant Interactions

Kelaprofen reduces the renal clearance of substances, resulting in increased plasma concentrations of both Lithium and Methotrexate as documented in labeling. The administration of Methotrexate requires a strict separation of at least 12 hours from Kelaprofen treatment.

Anticoagulants (e.g., Warfarin), Antiplatelet Agents, and Oral Corticosteroids carry an increased risk of hemorrhage or gastrointestinal bleeding when co-administered. Concomitant use with Diuretics or Antihypertensive Agents (e.g., ACE inhibitors) may reduce their efficacy and increase the risk of renal function impairment.

Food and Substance Interactions

Consumption of Alcohol (Ethanol) is associated with an increased risk of stomach bleeding. In patients with impaired renal function or in the elderly, the risk of interaction-related adverse events is officially documented as heightened.

Mechanism of Action

Kelaprofen's mechanism of action is focused entirely on modulating key molecular steps within the arachidonic acid cascade and associated physiological signaling pathways. The drug acts by interfering with the synthesis of biological mediators, influencing three major physiological response systems.

Kelaprofen operates as a non-selective, reversible competitive inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). By occupying the enzyme's active site, the drug prevents the conversion of arachidonic acid into various prostaglandins (PGs). This upstream action is important because PGs are chemical signals that contribute to heightened physiological responses and systemic inflammation, resulting in inhibition of the Prostaglandin synthesis cascade.

The reduction in prostaglandin levels directly influences afferent nerve activity. PGE2 normally sensitizes peripheral nociceptors (pain-sensing nerve endings) to chemical and mechanical stimuli; Kelaprofen's mechanism limits this sensitization. The reduction in prostaglandin-induced sensitization results in attenuated signal transmission from peripheral nociceptors.

A key component of the mechanism is the drug's effect in the brain's hypothalamus. By inhibiting PGE2 synthesis in this area, Kelaprofen removes the chemical signal that elevates the body's internal temperature set-point during an induced response. This allows the hypothalamus to reset the set-point back to a normal range, which causes an adjustment of the body's core temperature.

Dosage and Administration Information

How to Use Kelaprofen: Official Administration Guidelines

Kelaprofen is approved for administration via oral, topical, and parenteral routes, with the specific method determined by the official dosage form, which includes capsules, tablets, and topical gels. The general principle across all routes is to use the lowest effective dose for the shortest possible duration necessary for management.

Administration Scope

Instruction Category Official Guidelines
Route of administration Oral (Immediate-Release and Extended-Release forms), Topical (gel, patch), and Parenteral (IM or IV injection).
Dosing schedule (Adult) Immediate-Release (IR) forms are typically dosed at 25 mg to 50 mg every six to eight hours as needed for acute use. Maintenance dosing is 75 mg three times a day, with a maximum daily limit of 300 mg. Extended-Release (ER) forms are scheduled for 200 mg once daily.
Timing in relation to meals Oral immediate-release products may be taken with food, milk, or an antacid to minimize gastrointestinal upset.
Age-group administration rules The initial dose for older adults must be reduced. For patients with severe renal or hepatic impairment (serum albumin <3.5 g/dL), the maximum dose should not exceed 100 mg/day.
Special procedural conditions Extended-release tablets must be swallowed whole and must not be crushed. Topical gel should be applied with gentle massage and not covered by occlusive dressings.

Connection to the Overall Use Protocol

These official instructions establish the precise parameters—route, dosage amounts, frequency, and preparation—that define the standardized administration of the medicine. The instructions mandate using the lowest effective dose for the shortest duration and confirm that administration is determined by the specific formulation type (IR versus ER). This framework ensures that all usage complies with the established parameters for the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kelaprofen (Ketoprofen)

This section provides an overview of the types of official research evidence and clinical studies that have been conducted to evaluate the active ingredient Ketoprofen. The focus is on the design of the research, the measured outcomes, and the limitations noted in scientific literature, without offering personal advice or drawing conclusions about individual effectiveness.


Evidence for Acute Pain Relief

Research examining Ketoprofen for acute, sudden-onset pain primarily consists of short-term Randomized Controlled Trials (RCTs) and systematic reviews. These trials explored how symptom patterns related to acute discomfort change over time in populations with moderate-to-severe pain, such as following dental or minor surgical procedures.

Studies monitored patient-reported outcomes describing perceived discomfort, including measures of symptom intensity and the time required until patients reported a perceptible change. Studies report how symptoms evolved in the observed populations, with data show patterns related to measured outcomes during the first few hours after a single dose. What remains uncertain is the full picture of symptom patterns over extended periods, as follow-up durations were limited.

Evidence for Chronic Joint and Musculoskeletal Conditions

In the context of conditions characterized by fluctuating or episodic manifestations, such as osteoarthritis or rheumatoid arthritis, Ketoprofen was evaluated in intermediate-term RCTs and comparative studies.

Research examined outcomes reflecting daily functioning or activity level, as well as patient-reported outcomes describing perceived discomfort in the affected joints. Studies report how symptoms evolved in the observed populations over treatment courses that typically lasted between 6 and 12 weeks. Evidence contributes to the broader evidence landscape regarding symptom patterns over the medium term. What remains uncertain is the availability of dedicated research focusing solely on long-term functional patterns beyond these intermediate durations.

Summary of Research Gaps and Uncertainties

While a large body of evidence from RCTs contributes to the broader evidence landscape regarding short-term symptom patterns, evidence quality varies across studies, particularly when moving from acute, highly controlled surgical pain models to more complex chronic conditions. There is limited information for long-term outcomes, as many key trials focus on short- to intermediate-term relief. Research provides context but not individual predictions, and studies contribute to understanding symptom patterns, not guaranteeing a specific result for any one person.

Key Studies & References

  1. Ketoprofen - LiverTox - Clinical and Research Information on Drug-Induced Liver Injury (NIH)

Frequently Asked Questions (FAQ)

Common questions about Kelaprofen (FAQ)


Q: What is the chemical name for Kelaprofen?

Kelaprofen is the commercial designation for the active ingredient Ketoprofen. According to official government databases, its full chemical name is 2-(3-benzoylphenyl)propanoic acid. This substance is formally classified as a nonsteroidal anti-inflammatory drug (NSAID).


Q: What is the half-life of Kelaprofen in the body?

Regulatory documents indicate that the elimination half-life of Ketoprofen is relatively short, typically ranging from 1 to 3 hours in healthy, younger adults. This half-life describes the time required for the body’s plasma concentration of the drug to be reduced by fifty percent. Official information notes this elimination time may be longer in older patients.


Q: Why do some people say Kelaprofen makes them drowsy?

Official product information lists drowsiness, dizziness, and headache as common side effects affecting the Central Nervous System (CNS). Official labels include warnings that these effects may temporarily affect mental and physical abilities.


Q: Does Kelaprofen cause any issues with blood pressure?

Yes, official labeling indicates that Kelaprofen can lead to the new onset of high blood pressure (hypertension) or the worsening of pre-existing hypertension. Regulatory documents indicate that monitoring of blood pressure is recommended during treatment.


Q: Can Kelaprofen affect my liver test results?

The use of Kelaprofen may cause elevations in one or more routine liver tests, according to government health labels. Serious liver reactions, though rare, have been reported; these include conditions like jaundice or fatal hepatitis.


Q: Are there specific age restrictions for taking Kelaprofen?

Official regulatory information specifies that the safety and effectiveness of Kelaprofen have not been established in pediatric patients (those under 18 years of age).


Q: Is Kelaprofen available over-the-counter or only by prescription?

In the United States, Kelaprofen (Ketoprofen) is available only by prescription.


Q: Does Kelaprofen have generic versions available?

Yes, regulatory databases confirm that the active ingredient Ketoprofen is available in various generic formulations in multiple dosage forms.


Q: Why is Kelaprofen sometimes prescribed for arthritis?

Kelaprofen is formally approved for use in the treatment of the signs and symptoms associated with both rheumatoid arthritis and osteoarthritis. It is used to help manage the pain and inflammation related to these chronic joint conditions.


Q: Can women who are breastfeeding take Kelaprofen?

Information from the NIH Drugs and Lactation Database notes that Ketoprofen is present in human milk at very low levels. Due to reported adverse renal and gastrointestinal effects in breastfed infants, alternative agents are often used, especially for newborns or premature infants.


Q: What is the maximum duration Kelaprofen should be used for acute pain?

Regulatory guidance stresses that the drug should be used at the lowest effective dose for the shortest duration possible. Regulatory guidance emphasizes that the total duration of use should be minimized to reduce potential risks.


Q: What signs indicate an allergic reaction to Kelaprofen?

Signs of a serious allergic reaction, as described in official medication guides, may include hives, trouble breathing, or swelling of the face or throat. A severe allergic reaction is a medical emergency.


Q: Does Kelaprofen cause photosensitivity (increased sensitivity to the sun)?

Photosensitivity, which is an increased sensitivity of the skin to sunlight, has been reported as an adverse event in some postmarketing reports for Ketoprofen. This adverse event may require sun exposure precautions.


Q: Can Kelaprofen be used safely by people with mild kidney issues?

According to official drug monographs, patients with impaired kidney function may require a reduced maximum daily dose of Kelaprofen. Official drug information indicates that close monitoring of kidney function is necessary in these cases.


Q: Does the efficacy of Kelaprofen change if taken with food?

Official pharmacokinetic data indicates that taking the drug with food may slow the rate at which it is absorbed. This can delay the time it takes for the concentration in the blood to peak, though the total amount of drug absorbed is generally not affected.


Q: Are there any less common, but serious, side effects associated with Kelaprofen?

In addition to the major cardiovascular and gastrointestinal risks, regulatory documents note other serious but less common adverse effects. These include new or worsening kidney failure, anemia (low red blood cells), and severe, rare skin reactions.


Q: Why do some people use Kelaprofen for menstrual cramps?

Official regulatory labels include the management of mild-to-moderate pain as an approved use, and this specifically includes pain associated with dysmenorrhea (menstrual cramps).


Q: Has Kelaprofen been studied for post-operative pain management?

Studies and research evidence included in drug documents have investigated the effectiveness of Ketoprofen for pain relief following acute procedures, such as dental surgery or other minor surgical procedures.


Q: Is it normal for my urine to look different after starting Kelaprofen?

Rarely reported adverse events have included changes in urine appearance, such as cloudy urine, or changes in the amount of urine produced. These changes may be associated with kidney issues and are typically reported to a healthcare provider.


Q: Is Kelaprofen safe for people with asthma?

According to official contraindications, Kelaprofen must not be used in patients who have a known history of experiencing asthma, hives, or other allergic-type reactions after taking aspirin or other NSAIDs.


Q: Are there any known drug-drug interactions with common antidepressants and Kelaprofen?

Official drug interaction labels specify that taking Kelaprofen with certain antidepressants, such as SSRIs and SNRIs, may increase the risk of serious gastrointestinal bleeding. This combination is noted to require caution.


Q: Does taking Kelaprofen make you more susceptible to bruising?

Official adverse reaction reports confirm that easy bleeding or bruising is a reported side effect of Kelaprofen. This is due to the drug’s potential effect on the function of blood platelets.

How should Kelaprofen be stored and disposed of?

The storage and disposal of Kelaprofen solution for injection must strictly follow official regulatory guidelines to maintain its stability and ensure safe handling.

Storage Requirements

Official labeling mandates that the product must be stored below 25°C and must not be refrigerated or frozen. To prevent degradation, the vial must be protected from light by keeping it in the original outer carton.

Stability and Child Safety

The shelf life of the unopened product is 30 months. After the immediate container is first opened, the solution must be used within 28 days. The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired product should not be disposed of via wastewater or household waste. All disposal must comply with local requirements and applicable national collection systems for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kelaprofen found in:

A-Z Index: